Jaguar Health Files 8-K on New Agreement and Accountant Change

TL;DR

Jaguar Health signed a new deal and swapped accountants, filing an 8-K on 2/20.

AI Summary

Jaguar Health, Inc. filed an 8-K on February 20, 2025, reporting on two key events that occurred on February 19, 2025. The company entered into a Material Definitive Agreement and also made changes to its certifying accountant. Specific details of the agreement and the accountant change were not provided in this initial filing.

Why It Matters

This filing indicates significant corporate actions, including a new material agreement and a change in auditors, which could impact the company's financial reporting and strategic direction.

Risk Assessment

Risk Level: medium — Changes in material agreements and certifying accountants can signal underlying business shifts or financial scrutiny.

Key Numbers

• 001-36714 — Commission File Number (Jaguar Health's SEC filing identifier)
• 46-2956775 — IRS Employer Identification No. (Jaguar Health's tax identification number)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• 200 Pine Street Suite 400 (address) — Principal Executive Offices
• San Francisco, California (location) — Principal Executive Offices Location
• 415-371-8300 (phone_number) — Registrant's Telephone Number
• Jaguar Animal Health, Inc. (company) — Former Company Name

FAQ

From the Filing

0000950170-25-024228.txt : 20250220 0000950170-25-024228.hdr.sgml : 20250220 20250220165112 ACCESSION NUMBER: 0000950170-25-024228 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250219 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Changes in Registrant's Certifying Accountant FILED AS OF DATE: 20250220 DATE AS OF CHANGE: 20250220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25646264 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 jagx-20250219.htm 8-K 8-K false 0001585608 0001585608 2025-02-19 2025-02-19   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           200 Pine Street Suite 400   San Francisco , California   94104 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 371-8300     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 1.01 Entry into a Material Definitive Agreement. On February 13, 2025, Jaguar Health, Inc. (the “Company”) and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “Note Amendment”) with Streeterville Capital, LLC (“Streeterville”) to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same p